Darwin AG (7V0) - Net Assets
Based on the latest financial reports, Darwin AG (7V0) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 7V0 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | 16.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 41.59 |
Darwin AG - Net Assets Trend (2021–2023)
This chart illustrates how Darwin AG's net assets have evolved over time, based on quarterly financial data. Also explore how large is Darwin AG's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Darwin AG (2021–2023)
The table below shows the annual net assets of Darwin AG from 2021 to 2023. For live valuation and market cap data, see how much is Darwin AG worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €93.77 Million ≈ $109.63 Million |
-17.85% |
| 2022-12-31 | €114.14 Million ≈ $133.45 Million |
+65.34% |
| 2021-12-31 | €69.04 Million ≈ $80.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Darwin AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 52.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €73.06 Million | 77.83% |
| Other Components | €20.81 Million | 22.17% |
| Total Equity | €93.88 Million | 100.00% |
Darwin AG Competitors by Market Cap
The table below lists competitors of Darwin AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lotte Himart
KO:071840
|
$125.59 Million |
|
Keyrus SA
PA:ALKEY
|
$125.61 Million |
|
Lippo General Insurance Tbk
JK:LPGI
|
$125.69 Million |
|
Global Green Chemicals Public Company Limited
BK:GGC
|
$125.71 Million |
|
Synalloy Corporation
NASDAQ:ACNT
|
$125.57 Million |
|
Apyx Medical Inc
NASDAQ:APYX
|
$125.55 Million |
|
Silicom
NASDAQ:SILC
|
$125.54 Million |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
$125.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Darwin AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 112,015,013 to 93,875,063, a change of -18,139,949 (-16.2%).
- Net income of 39,713 contributed positively to equity growth.
- Dividend payments of 2,536,718 reduced retained earnings.
- Other factors decreased equity by 15,642,945.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €39.71K | +0.04% |
| Dividends Paid | €2.54 Million | -2.7% |
| Other Changes | €-15.64 Million | -16.66% |
| Total Change | €- | -16.19% |
Book Value vs Market Value Analysis
This analysis compares Darwin AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.40x to 0.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €22.91 | €9.05 | x |
| 2022-12-31 | €37.34 | €9.05 | x |
| 2023-12-31 | €31.29 | €9.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Darwin AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.22%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.91x
- Recent ROE (0.04%) is below the historical average (22.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 28.21% | 17.42% | 0.69x | 2.35x | €12.52 Million |
| 2022 | 40.24% | 20.61% | 0.98x | 2.00x | €33.87 Million |
| 2023 | 0.04% | 0.22% | 0.10x | 1.91x | €-9.35 Million |
Industry Comparison
This section compares Darwin AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Darwin AG (7V0) | €- | 28.21% | N/A | $125.57 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Darwin AG
Darwin AG operates in the healthcare industry. The company offers dietary supplements and cosmetics products. It also provides consulting and support services. The company was incorporated in 2021 and is based in Munich, Germany.